Summary
KRAS has the distinction of being a preeminent oncoprotein as it is mutated in more than 85% of RAS-altered cancers. The RAS (G12D Mutant) antibody [HL10] is the first commercially available recombinant antibody that demonstrates exceptional specificity by paraffin-embedded immunohistochemistry and western blot for the RAS G12D mutant protein.
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:500-1:3000 |
Assay dependent |
1:25-1:100 |
Note :
WB
Suggest using high sensitivity ECL for optimization. GTX14698 Trident femto Western HRP Substrate is recommended.
|
Not tested in other applications.
Positive Control
293T transfected NRAS(G12D) , AsPC1 , HPAC , HPAF-II , PANC1 , SU86.86
Form
Liquid
Buffer
PBS
Preservative
No Preservative
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1.5 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Carrier-protein conjugated synthetic peptide surrounding mutant G12D of human K-Ras. The exact sequence is proprietary.
Purification
Affinity purified by Protein A.
Conjugation
Unconjugated
RRID
AB_2888515
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.